Cargando…
Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report
Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp,...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189013/ https://www.ncbi.nlm.nih.gov/pubmed/37207136 http://dx.doi.org/10.3389/fonc.2023.1167791 |
_version_ | 1785042991194308608 |
---|---|
author | Reiter, Selina Schroeder, Christopher Broche, Julian Sinnberg, Tobias Bonzheim, Irina Süsskind, Daniela Flatz, Lukas Forschner, Andrea |
author_facet | Reiter, Selina Schroeder, Christopher Broche, Julian Sinnberg, Tobias Bonzheim, Irina Süsskind, Daniela Flatz, Lukas Forschner, Andrea |
author_sort | Reiter, Selina |
collection | PubMed |
description | Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM. |
format | Online Article Text |
id | pubmed-10189013 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-101890132023-05-18 Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report Reiter, Selina Schroeder, Christopher Broche, Julian Sinnberg, Tobias Bonzheim, Irina Süsskind, Daniela Flatz, Lukas Forschner, Andrea Front Oncol Oncology Metastatic uveal melanoma (UM) is a rare form of melanoma differing from cutaneous melanoma by etiology, prognosis, driver mutations, pattern of metastases and poor response rate to immune checkpoint inhibitors (ICI). Recently, a bispecific gp100 peptide-HLA-directed CD3 T cell engager, tebentafusp, has been approved for the treatment of HLA-A*02:01 metastatic or unresectable UM. While the treatment regime is complex with weekly administrations and close monitoring, the response rate is limited. Only a few data exist on combined ICI in UM after previous progression on tebentafusp. In this case report, we present a patient with metastatic UM who first suffered extensive progression under treatment with tebentafusp but in the following had an excellent response to combined ICI. We discuss possible interactions that could explain responsiveness to ICI after pretreatment with tebentafusp in advanced UM. Frontiers Media S.A. 2023-05-03 /pmc/articles/PMC10189013/ /pubmed/37207136 http://dx.doi.org/10.3389/fonc.2023.1167791 Text en Copyright © 2023 Reiter, Schroeder, Broche, Sinnberg, Bonzheim, Süsskind, Flatz and Forschner https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Reiter, Selina Schroeder, Christopher Broche, Julian Sinnberg, Tobias Bonzheim, Irina Süsskind, Daniela Flatz, Lukas Forschner, Andrea Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title_full | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title_fullStr | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title_full_unstemmed | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title_short | Successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
title_sort | successful treatment of metastatic uveal melanoma with ipilimumab and nivolumab after severe progression under tebentafusp: a case report |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189013/ https://www.ncbi.nlm.nih.gov/pubmed/37207136 http://dx.doi.org/10.3389/fonc.2023.1167791 |
work_keys_str_mv | AT reiterselina successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT schroederchristopher successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT brochejulian successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT sinnbergtobias successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT bonzheimirina successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT susskinddaniela successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT flatzlukas successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport AT forschnerandrea successfultreatmentofmetastaticuvealmelanomawithipilimumabandnivolumabaftersevereprogressionundertebentafuspacasereport |